Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 25917733)

Published in Urology on May 01, 2015

Authors

Yejin Mok1, Heejin Kimm2, Sang Yop Shin3, Sun Ha Jee4, Elizabeth A Platz5

Author Affiliations

1: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Epidemiology and Health Promotion and Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea.
2: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
3: Korea Medical Institute, Seoul, Korea.
4: Department of Epidemiology and Health Promotion and Institute for Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea. Electronic address: jsunha@yuhs.ac.
5: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

Articles citing this

What's new in screening in 2015? Curr Opin Urol (2016) 0.77

Articles cited by this

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05

Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60

Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60

Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat (2013) 7.11

Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer (2013) 6.23

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA (1993) 5.77

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15

Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69

Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol (2011) 2.53

Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA (2014) 2.42

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology (2001) 2.38

Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2011) 2.19

Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer (2010) 2.13

Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol (2011) 1.88

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol (1994) 1.63

Screening for prostate cancer. CA Cancer J Clin (2009) 1.48

Prostate cancer in Asian men. Nat Rev Urol (2014) 1.46

Total and percent free prostate-specific antigen levels among U.S. men, 2001-2002. Cancer Epidemiol Biomarkers Prev (2005) 1.21

The Korean Heart Study: rationale, objectives, protocol, and preliminary results for a new prospective cohort study of 430,920 men and women. Eur J Prev Cardiol (2013) 1.08

Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev (2008) 0.92

Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. J Natl Cancer Inst (2004) 0.82

Prostate-specific antigen and prostate cancer mortality: a systematic review. Am J Prev Med (2013) 0.80

PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia. Urol Clin North Am (1993) 0.80